By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

A Quick Take On Maze Therapeutics, Inc. Maze Therapeutics, Inc. (MAZE) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is ...

Maze Therapeutics has filed for an initial public offering with the Securities and Exchange Commission. The San Francisco-based human genetics biotech company didn't say Tuesday how many shares it ...

Maze Therapeutics looks to steer lead kidney disease assets through the clinic with $115M series D Maze also hopes to use the IPO to boost its Compass platform, which uses human genetic variation ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

Jan 7 (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public offering (IPO ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

(Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States. The South San Francisco, ...